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In this issue of NDT, Kondo et al. [1] address a clinically rele-
vant topic, which has been rarely studied so far in the chronic
kidney disease (CKD) population: the use of potentially in-
appropriate medications (PIMs). In particular, they studied
the frail subset of elderly haemodialysis subjects, who are more
exposed to the potentially severe adverse effects of medication
errors, especially when multiple therapies are prescribed.
The study of Kondo refers to 1367 elderly patients with a
median age of 72 years and a range of 65–98 years [1], reﬂect-
ing the European prevalent dialysis population, including
many old or very old patients.
Elderly people are at higher risk of side effects even for a
single drug for many pharmacokinetic reasons. A healthy
40-year-old subject has a total body water content of 55% of
body weight (women) or 60% (men), progressively declining
to 50% in men and even less in women by the age of 75 years
and more [2]. Consequently, the same dose of a drug given to
a healthy adult, in a very old person will reach higher blood
concentrations, thus increasing the risk of side effects. In add-
ition, the elimination of hydro-soluble drugs through the
kidney is reduced in the elderly due to decreased renal mass
[3], cortical blood ﬂow [4] and glomerular ﬁltration rate [5].
Although these considerations do not apply to the patients
studied by Kondo, all on haemodialysis and therefore func-
tionally anephric, they must be considered when treating
elderly persons with reduced or even apparently normal
kidney function.
On the contrary, the fat-soluble drugs have a greater
volume of distribution in older people due to a higher percent-
age of body fat. The liver plays a major role in fat-soluble drug
clearance and ageing has been reported to reduce hepatic
blood ﬂow and the clearance capacity, particularly for those
drugs that undergo oxidation by the microsomal cytochrome
P450 isoform CYP3A-dependent monooxygenase system [6].
Moreover, we do not have any formulae to measure liver func-
tion like those available for kidney function.
Another point to be considered when examining the poten-
tial risk of adverse effects of drugs is that the elderly are often
malnourished or at risk of malnutrition: when their serum
albumin concentration is reduced, the capacity to bind drugs
is also reduced, increasing their free fraction. Consequently,
more drug becomes available to reach receptors, thus increas-
ing the pharmacologic effect in an elderly individual.
Loss of attention and memory of elderly people not ad-
equately assisted by partners or caregivers who give a further
contribution to increase the risk of under but also over inges-
tion of drugs.
An increased risk of adverse drug reactions (ADRs) in the
elderly also derives from two other factors: the exclusion of
elderly patients from large randomized controlled trials testing
new medications and the high number of drugs prescribed to
the elderly, which can be difﬁcult to discontinue for the pres-
ence of multiple comorbidities. Therefore, the pharmacology
of many medications has not been studied sufﬁciently in
elderly adults and, not surprisingly, the risk of developing an
ADR is estimated to be ∼20% and ADRs requiring hospitaliza-
tion is ∼10.7% for elderly patients, when compared with 5.3%
for the general population [7]. Table 1 shows the main classes
of drugs, which most commonly determine adverse events.
Comparisons should be approached with caution, due to dif-
ferent classiﬁcation criteria used by the different authors
[8–10]. In fact, the ranked lists of the individual groups of
drugs are quite different: heparin, insulin/hypoglycaemic
agents, warfarin and digoxin [11]; cardio-tonic glycosides,
adrenal corticosteroids, anti-neoplastic agents, anticoagulants
and analgesics [9]; loop diuretics, opioids, steroids, antibiotics,
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oral anticoagulants and beta-agonist inhaled [12], non-
steroidal anti-inﬂammatory drugs (NSAIDs), diuretics, antic-
oagulants, angiotensin-converting-enzyme (ACE) inhibitors/
angiotensin-receptor blockers, opiates and digoxin [13] and
oral anticoagulants, insulin, anti-platelets, oral hypoglycaemic
agents and opioids [9].
The most common causes of ADR in elderly patients are
the unwanted interactions among the many medications
taken, due to the high number of diseases or co-morbidities,
such as ischaemic heart disease, peripheral and cerebral vascu-
lar disease and diabetes. Various studies have documented a
direct correlation between the number of medications and the
risk of an ADR. The potential drug interaction risks when pa-
tients are taking 2–3, 4–5 and 6–7 medications are 39, 89 and
100%, respectively [14], also as a consequence of pharmacoki-
netic and pharmacodynamic changes. Thus, elderly patients
are inevitably at risk of numerous ADR [7, 15–17].
The most common negative drug interactions reported in
the literature are the following: hyperkalaemia due to ACE in-
hibitors/angiotensin-receptor blockers and potassium-sparing
diuretics or sulfamethoxazole–trimethoprim or quinolones,
hypotension and shock with calcium-channel blockers plus
macrolide antibiotics, increase digoxin toxicity with macrolide
antibiotics lithium toxicity due to association with ACE inhibi-
tors or diuretics or NSAIDs [18–20].
Because of the difﬁculties in deﬁning the correct dose
of drugs for elderly patients, inadequate interventions of
the physician can result in inappropriate dosing, duration of
therapy, lack of attention to other prescribed drugs, leading
to clinically signiﬁcant ADR, drug–drug and drug–disease
interactions [21].
Moreover, in elderly CKD and haemodialysis patients, the
presence of many co-morbidities, each of them requiring spe-
ciﬁc therapies, leads to the possible prescription of a high
number of drugs. Some of them could be indicated for one co-
morbidity but contraindicated in the presence of another one.
Thus, the composition of a list of PIMs is complex, but neces-
sary to avoid the risk of many ADRs. Moreover, haemodialysis
patients have the big problem of a quite different pharmaco-
kinetics due to the lack of the excretory renal function and the
intermittent clearing effect of dialysis.
Drugs are considered appropriate if their expected beneﬁts
outweigh the potential risks. The elderly, and even more
elderly patients affected by CKD, are particularly prone to
drug-related adverse events. Thus, lists of drugs have been pro-
posed for avoiding medications whose risks outweigh beneﬁts
among the elderly. These drugs, also deﬁned as ‘medications
with no clear evidence-based indication, and which carry a
substantially higher risk of adverse side-effects or are not cost-
effective’, correspond to the term ‘potentially inappropriate
medication’ [22].
The most commonly used list derives from the Beers cri-
teria, originally developed by geriatrician Mark Beers [23, 24],
which have been recently updated and revised by the Ameri-
can Geriatrics Society [25]. Fifty-three medications or medica-
tion classes encompass the ﬁnal updated criteria divided into
three categories: PIM and drug classes to avoid in older adults,
PIM and drug classes to avoid in older adults with certain dis-
eases and syndromes that the drugs listed can exacerbate and
ﬁnally medications to be used with caution in older adults.
In Europe, the STOPP (Screening Tool of Older People’s
potentially inappropriate Prescriptions) [22, 26] and START
(Screening Tool to Alert doctors to the Right Treatment) cri-
teria [27] have been developed, because of lack of signiﬁcant
and consistent associations between Beers criteria for PIMs
and adverse drug events. STOPP and START criteria appear to
be more appropriate in the clinical setting, as they address not
only potentially inappropriate drugs, but also under-treatment
due to lack of prescribing necessary medications.
STOPP comprises 65 clinically signiﬁcant criteria for po-
tentially inappropriate prescribing in elderly people [22, 26].
Each criterion is accompanied by a concise explanation as to
why the prescribing practice is potentially inappropriate.
START consists of 22 evidence-based prescribing indicators
for commonly encountered diseases in older people.
Kondo et al. [1] applied the Beers criteria to elderly haemo-
dialysis patients, focusing on the three most frequently pre-
scribed PIMs: H2 blockers, anti-platelet agents and α-blockers,
and tried to determine which characteristics of either the
patient or the facility were associated with PIM prescriptions.
Teaching hospitals and facilities conducting multidisciplinary
rounds were associated with a lower prevalence of PIM. While
the initiative of Kondo et al. should be applauded, we feel that
their ﬁndings are just the tip of the iceberg, because many
drugs are potentially inappropriate in dialysis patients, but
they are not listed in the Beers criteria. Several drugs may be
more problematic in dialysis patients for one or more of the
following reasons: inability to be excreted by the kidneys
(either as basal drug or its metabolites); higher probability of
clinically relevant drug interactions; adverse reactions more
common in patients in renal failure and renal failure affects
drugs transport, altering their bioavailability [28]. In CKD pa-
tients, one area that deserves special attention is pain manage-
ment, as both under-treatment and misuse of drugs are
frequent [29, 30].
In the cohort studied by Kondo et al., selected PIMs were
prescribed to more than half of the patients, indicating the
need for further investigations on a larger number of drugs in
elderly people receiving haemodialysis. The same is probably
Table 1. Drugs most likely determining adverse events
Ref. [8] Ref. [9] Ref. [10]
Percentage of
all ADRs
Percentage of
all ADRs
Percentage of
hospitalizations
due to ADR
Analgesics, antipyretics
and anti-rheumatics
8.0 13.3 NR
Endocrine agents 11.0 14.1 22.8
Cardiovascular drugs 21.6 11.5 9.8
Oral anticoagulants 7.4 10.3 42.3
Anti-neoplastic and
immunosuppressive
8.1 10.1 2.9
Antibiotics 4.7 6.3 3.8
Central nervous system
drugs
7.5 4.3 9.7
ADR, adverse drug reaction; NR, not reported.
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true for patients with CKD not on dialysis. Jones and Bhandari
[31] found that in elderly patients with CKD (mean estimated
glomerular ﬁltration rate 17.2 mL/min/1.73 m2; range 4–44),
prevalence of PIM according to the Beers criteria was 13%,
lower than that reported in dialysis patients, but still relevant.
Some of the consequences of PIM can be severe, such as drug-
induced falls.
The main limitations of the study by Kondo et al. are the
lack of data about the association of PIM and clinical out-
comes, as well as the lack of generalizability since all patients
were Japanese and were followed in selected centres participat-
ing to the Dialysis Outcome Practice Pattern Study in Japan.
In the USA, ADRs result in over 700 000 visits to hospital
emergency rooms and 120 000 hospitalizations each year [32].
Costs of ambulatory (non-hospital settings) ADR are also sig-
niﬁcant, and at least 40% of them may be preventable [33]. The
seriousness of ADR-related public health problems led the
Centers for Disease Control and Prevention to establish a medi-
cation safety programme (http://www.cdc.gov/medicationsafety/
). In elderly dialysis patients, ADRs and the use of PIMs might
be an even greater problem. In this respect, we highlight some
practical considerations in Table 2.
In conclusion, we strongly support the notion that more
studies are needed on the problem of PIMS in dialysis patients,
especially in the elderly. As many adverse drug events can be
prevented, it could be extremely useful to develop speciﬁc PIM
criteria for dialysis patients, identifying those medications that
could be withdrawn, thus reducing the pill burden and, at the
same time, increasing the safety of our patients.
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Table 2. PIMs in haemodialysis: recommendations for the nephrologist
Drug handling in CKD and dialysis patients is an underestimated issue
among physicians.
There is a high risk of prescribing PIMs.
Practicing nephrologists should be familiar with the concept of PIM.
Kondo et al. highlighted some of them (H2 blockers, anti-platelet agents
and α-blockers), but the peculiar pharmacokinetic and
pharmacodynamics features of drugs in dialysis patients may widen the
number of problematic drugs in this patient population. Analgesic drugs
are a typical example of a class with important prescribing limitations
and side effects for some of them.
STOPP [22, 26] and START [ 27] criteria, which could be adapted to the
dialysis population, should be considered by the practicing nephrologist,
as they address not only potentially inappropriate drugs, but also
potential under-treatment due to lack of prescribing necessary
medications.
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